Small molecule · Agonist of Muscarinic acetylcholine receptor · developed by Lenz Therap
Aceclidine is a cholinergic muscarinic agonist that stimulates muscarinic receptors on smooth muscle. It is a predominantly pupil-selective miotic that acts on the iris sphincter muscle, causing contraction that produces a pinhole effect. It is studied in presbyopia and other refractive error and eye conditions.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Jan 14, 2026). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05728944 | Phase 3 | Presbyopia | Completed | LENZ |
| NCT03201562 | Phase 2 | Presbyopia | Completed | LENZ |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Eye DiseasesNear VisionPresbyopiaRefractive Error
Updated Oct 18, 2026. Something wrong or missing? Report it on the LENZ page.
See LENZ's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LENZ catalysts and pipeline →